Gilead Sciences Inc


This Company Proves the "Ten-Bagger Stock" Is No Myth

Back in August 2011, for the very first edition of Private Briefing, I recommended a Belgian biotech firm that I said was "like buying an independent drug development lab" for less than nine bucks a share – $8.60, in fact.

I zeroed in on the company's collaborative partnerships on a whole slew of drug development programs.

Now, I love to see this in a biotech stock, because it means that some of the usual risks of owning a small, clinical-stage company – running out of money, or the risk of one trial failure wiping out the firm – were minimized.

That arrangement was critical in the massive, almost tenfold gains that followed. (And, as you'll see, it's going to be just as important in the bigger gains I see down the road for the folks who bought this company.)

I've recommended these shares for my subscribers more than a dozen times since, each time before a fresh bumper crop of profits. This company has given more than 931% in peak gains for Private Briefing subscribers, and a market-crushing 26% since I first shared it with Money Morning Members in September 2016.

There's a very specific reason I see these gains getting even bigger for everyone in the future...


Celebrate This High-Profit Milestone with Some More Triple-Digit Gains

This was the very first stock we recommended on the very first day Private Briefing was published – Aug. 11, 2011.

On that day, you could've owned it for less than nine bucks a share – $8.60.

That's a distant memory.

We've re-recommended these shares more than a dozen times since then, so successive "classes" of our readers can participate in these gains.

And sure enough, this stock hit an all-time high at midday yesterday… up a whopping 717% from that first day we wrote about it.

Let me tell you the ticker - and why I think there's a lot more profit in store for this "classic" pick...


Grab Gilead Sciences Stock Before Its Next 66.5% Climb (Nasdaq: GILD)

Sometimes Washington triggers a stock move that can hand us outsized gains. That's exactly what happened with Gilead Sciences Inc. (Nasdaq: GILD).

In March 2014, U.S. Rep. Henry Waxman (D-CA) lashed out at the cost of Gilead's newly approved Hepatitis C (HCV) drug, Sovaldi. Sovaldi runs $84,000, or $1,000 a pill.

But Waxman missed the obvious. Sovaldi (and its newer version Harvoni) cures 90% of HCV patients. That means patients can avoid the need for a liver transplant – an operation that runs $250,000 if an organ donor is found. And that price doesn't include antirejection drugs and antibiotics people must take for the rest of their lives.

Still, Gilead sold off on fears that its high cost would make Medicare look to another HCV drug maker with a less expensive solution. GILD stock lost 13% of its value in a matter of days.

Wall Street was dead wrong…

Medicare actually spent $4.6 billion on Hepatitis C treatments in the first six months of this year. That's almost as much as the agency spent in all of 2014. Gilead accounted for 66% of all covered prescriptions.

And since April 2014, Gilead has gained 66.5% – more than four times that of the S&P 500.

Simply put, Gilead dominates the HCV sector. And as I'll show you today, opportunities for the firm are growing faster...